Healthcare / Medical Care FacilitiesBSE
$3.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-73.0M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$164M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-328.0%
↓Gross Margin
561.3%
↑Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-42.7%
FCF CAGR
—
FCF margin
-222.5%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $79.0M · net income $-441.5M · FCF $-175.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $79.0M | $79.0M | $400.1M | $420.4M | $420.7M |
| Net Income | $-441.5M | $-441.5M | $125.5M | $52.6M | $52.0M |
| EBITDA | $-430.5M | $-430.5M | $99.4M | $93.1M | $89.3M |
| EPS | -8.17 | -8.17 | 2.32 | 1.56 | 1.62 |
| Gross Margin | 561.3% | 561.3% | 62.4% | 62.7% | 63.2% |
| Operating Margin | 348.8% | 348.8% | 13.4% | 16.6% | 17.4% |
| Net Margin | -558.5% | -558.5% | 31.4% | 12.5% | 12.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.06 | 0.09 | 0.30 |
| Current Ratio | 1.18 | 1.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-175.9M | $-175.9M | $-8.2M | $-73.0M | $13.5M |
| Returns | |||||
| ROE | -328.0% | -328.0% | 21.5% | 11.5% | 36.5% |
| Valuation | |||||
| P/E | — | — | 3.50 | 7.82 | 12.71 |
| EV/EBITDA | — | — | 3.03 | 5.47 | 7.86 |
| P/B | 1.22 | 1.22 | 0.75 | 1.44 | 4.64 |
| Growth & Yield | |||||
| Revenue Growth | -80.2% | -80.2% | -4.8% | -0.1% | — |
| EPS Growth | -452.2% | -452.2% | 48.7% | -3.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.0%
Start / end P/E
n/dx → n/dx
EPS bridge
2.32 → -8.17
Residual
-30.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.